Business Wire

VA-REGULA

15.2.2024 08:01:33 CET | Business Wire | Press release

Share
Frost & Sullivan Awards Regula: Excellence in Best Practices, 2024 Global Enabling Technology Leader

Frost & Sullivan recognizes companies with Best Practices Awards in various categories for outstanding efforts to inspire growth in their industries. Businesses that earn these awards identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. Frost & Sullivan considers these companies to be the game changers.

As for the Enabling Technology Leadership Award in the identity verification (IDV) industry, Frost & Sullivan applies a rigorous analytical process to assess multiple nominees. This involves a detailed evaluation of best practices criteria across two dimensions: Technology Leverage and Customer Impact. Frost & Sullivan points out that Regula excels in many of the criteria in the IDV solutions space.

Synergizing cutting-edge verification technologies with an intuitive user-centric design. Experts emphasize Regula's product portfolio, seamlessly integrating a single-vendor solution for complete identity verification based on biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with enhanced authenticity validation, along with forensic devices dedicated to in-depth examination. At the heart of Regula’s IDV solution lies the most comprehensive database encompassing over 13,500 documents from 247 countries and territories, supporting over 138 languages.

Regula distinguishes itself by fostering innovation through in-house development of all technologies, steering clear of third-party dependencies. Notably, its standout feature is the platform-agnostic nature of its digital identification solutions. This enables customers to orchestrate an enhanced ID verification process effortlessly on any platform—be it mobile, web, desktop platforms, or passport readers.

Forging strategic alliances with renowned international organizations. Regula forges strategic partnerships with esteemed organizations like the International Air Transport Association, International Organization for Migration, and International Civil Aviation Organization. This collaborative effort establishes Regula as an integral player in a symbiotic exchange of insights and vital information about documents. This ongoing collaboration serves as a catalyst for continuously refining its technologies, positioning the company at the forefront of innovation.

Transforming customer workflows in many industries through value-driven verification solutions. Regula's distinctive offering lies in its rich heritage in the forensics space. The one-stop-shop nature of Regula’s solutions eradicates the necessity for customers to enlist multiple vendors for additional security measures and ensures a comprehensive strategy addressing security, forensics, and identity verification requirements in a seamless and integrated manner.

Enduring excellence through long-term customer relationships. Regula’s value-driven identity verification solutions extend across a spectrum of industry verticals, including banking, fintech, aviation, telecommunication, government authorities, healthcare, insurance, forensic labs, gambling, and others. The company's achievements are evidenced by providing hardware and software solutions for digital identity verification to a global network of over 1,000 organizations and 80 border control authorities. Notably, Regula's clientele includes major players such as the largest private bank globally, and prominent airline companies like AirAsia and WizzAir. Also, Regula has solidified its position as a trusted technology partner for several years at the Mobile World Congress (MWC), a premier international industry event organized by the GSMA.

On top of this, Frost & Sullivan believes Regula outperforms in responding to the complex landscape of identity fraud. Rabin Dhakal, Frost & Sullivan Best Practices Research Analyst states: “In the face of an escalating wave of sophisticated fraud, identity theft, and scams, the urgency for a robust identity verification solution has never been more pronounced. Frost & Sullivan believes that Regula’s proactive response to the evolving landscape of document fraud and fakes is unprecedented.”

"We are truly honored to be acknowledged by a prominent expert in market growth and innovations. We strive to emphasize the key differentiator for Regula, which lies in the wealth of experience gained over three decades - specifically in understanding documents and verification processes, our comprehensive document template database, full-cycle in-house production, and the team of top-notch forensic experts. These are the assets that enable us to drive continuous innovation and provide a comprehensive solution to identity verification,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about the 2024 Frost & Sullivan Global Enabling Technology Leadership Award in the identity verification solutions industry, please read the report.

About Frost & Sullivan

Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214825831/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye